4 Midcap Steady Revenue Growth Stocks to Watch for Future Multibagger Potential: Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs

Steady revenue growth stocks to watch for multibagger potential start with a simple filter: size, a clean financial record and earnings that keep growing. Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs meet that test, with market caps from Rs 31,620 crore to Rs 85,241 crore and Max Healthcare offering the largest market cap at Rs 85,241 crore. Each of these companies has a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and FY26 revenue growth between 10 and 20 per cent, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, and net profit rose in FY26 and in the latest quarter.

This list covers companies with a market capitalisation between Rs 30,000 crore and Rs 1,00,000 crore and FY26 revenue growth between 10 and 20 per cent, a return on equity of at least 10 per cent and profit growth in FY26 and in the latest quarter, rising profit in FY26 and the latest quarter, and complete, verifiable financials, ranked by market capitalisation. Each company has a market cap between Rs 30,000 crore and Rs 1 lakh crore. Investors screening steady revenue growth stocks usually begin with size and balance sheet strength, and this list follows the same logic. All figures are as of 26 October 2026 and are drawn from NSE and BSE data and company filings.

Click Here – Get Free Investment Predictions

What Are Steady Revenue Growth Stocks and Why Do They Attract Multibagger Interest?

Steady revenue growth stocks are shares of mid sized companies whose sales grew by 10 to 20 per cent in FY26, a steady pace that large and mid sized businesses can sustain year after year. The four here cover hospitals, shipbuilding and diagnostics.

Growth in the teens is easier to sustain than a sudden spike, and it usually reflects broad demand rather than a one-off. For steady revenue growth stocks, both FY26 and the latest quarter showed growth. Whichever way you read steady revenue growth stocks, the common thread is rising profit backed by complete financial data. A sensible way to study steady revenue growth stocks is to look at profit growth, returns and valuation side by side. Below, each of steady revenue growth stocks gets its own breakdown of growth, returns and valuation. Treat steady revenue growth stocks as a research list, since share prices and rankings change with every earnings season.

Steady Revenue Growth Stocks at a Glance: Price, Market Cap, PE and ROE

Prices are closing prices as of 26 October 2026. Mazagon Dock combines the lowest PE of the group, 28.99, with the highest return on equity, 26.48%.

Stock	CMP (Rs)	Market Cap (Rs Cr)	PE	Industry PE	ROE	Debt to Equity	52-Week Range (Rs)
Max Healthcare Institute	835	85,241	58.50	60.75	13.42%	0.32	815.00 to 1,221.90
Mazagon Dock Shipbuilders	1,875	82,736	28.99	48.92	26.48%	0.05	1,860.00 to 2,881.80
Fortis Healthcare	734.70	55,926	52.24	60.75	10.53%	0.35	565.00 to 757.40
Dr Lal PathLabs	1,855.60	31,620	57.88	60.75	20.13%	0.08	1,272.60 to 2,038.60

Max Healthcare: 24.26% Profit CAGR Since FY22

Max Healthcare Institute runs a network of multi-speciality hospitals in Delhi NCR, Mumbai and other cities. It reported FY26 revenue of Rs 8,536.07 crore, up 18.82% year on year, and net profit of Rs 1,442.41 crore, up 34.07%. Net profit has compounded at 24.26% a year since FY22, while revenue has grown 20.42% a year. Operating margin was 28.15% in FY26. The debt-to-equity ratio is 0.32.

In the June 2026 quarter, revenue rose 16.60% to Rs 2,406.69 crore and net profit grew 4.87% to Rs 322.96 crore. The share price has gained 149.91% over five years. Domestic institutions raised their holding from 17.42% in June 2025 to 29.96% in June 2026. The stock trades at a PE of 58.50 against an industry PE of 60.75, below the sector average, with a return on equity of 13.42%.

Mazagon Dock: 44.01% Profit CAGR Since FY22

Mazagon Dock Shipbuilders builds warships and submarines for the Indian Navy and is a key defence shipyard. It reported FY26 revenue of Rs 14,145.71 crore, up 12.77% year on year, and net profit of Rs 2,421.88 crore, up 6.35%. Net profit has compounded at 44.01% a year since FY22, while revenue has grown 23.18% a year. Operating margin was 26.20% in FY26. The debt-to-equity ratio is 0.05, which keeps interest costs low.

The stock trades at a PE of 28.99 against an industry PE of 48.92, below the sector average, with a return on equity of 26.48%. In the June 2026 quarter, revenue rose 10.40% to Rs 3,255.88 crore and net profit grew 22.12% to Rs 512.04 crore. The share price has gained 1461.53% over five years. Promoters hold 81.22%, which keeps ownership stable.

Fortis Healthcare: Five-Year Gain of 241.47%

Fortis Healthcare operates a chain of hospitals and diagnostic centres across India. It reported FY26 revenue of Rs 9,178.50 crore, up 16.93% year on year, and net profit of Rs 1,064.19 crore, up 31.48%. Net profit has compounded at 7.73% a year since FY22, while revenue has grown 12.43% a year. Operating margin was 22.41% in FY26. The debt-to-equity ratio is 0.35.

In the June 2026 quarter, revenue rose 17.29% to Rs 2,559.50 crore and net profit grew 2.26% to Rs 272.80 crore. The share price has gained 241.47% over five years. Domestic institutions raised their holding from 29.79% in June 2025 to 32.23% in June 2026. The stock trades at a PE of 52.24 against an industry PE of 60.75, below the sector average.

Dr Lal PathLabs: Return on Equity of 20.13%

Dr Lal PathLabs is one of India's leading diagnostic chains, running laboratories and collection centres across the country. It reported FY26 revenue of Rs 2,864.18 crore, up 12.11% year on year, and net profit of Rs 509.75 crore, up 3.56%. Net profit has compounded at 9.83% a year since FY22, while revenue has grown 7.56% a year. Operating margin was 30.90% in FY26. The debt-to-equity ratio is 0.08, which keeps interest costs low.

The stock trades at a PE of 57.88 against an industry PE of 60.75, below the sector average, with a return on equity of 20.13%. In the June 2026 quarter, revenue rose 18.87% to Rs 829.60 crore and net profit grew 27.24% to Rs 170.50 crore. The share price is up 19.11% over the past year. Domestic institutions raised their holding from 17.91% in June 2025 to 21.59% in June 2026.

Steady Revenue Growth Stocks: Financial Comparison on Growth and Margins

The table compares scale and growth across these steady revenue growth stocks. Latest quarter means the most recent reported quarter for each company, and only metrics that are positive for every company are shown.

Stock	Revenue (Rs Cr)	Net Profit (Rs Cr)	Revenue Growth (YoY)	4-Year Revenue CAGR	4-Year Net Profit CAGR	Operating Margin (Latest Quarter)
Max Healthcare	8,536.07	1,442.41	18.82%	20.42%	24.26%	27.00%
Mazagon Dock	14,145.71	2,421.88	12.77%	23.18%	44.01%	25.82%
Fortis Healthcare	9,178.50	1,064.19	16.93%	12.43%	7.73%	22.22%
Dr Lal PathLabs	2,864.18	509.75	12.11%	7.56%	9.83%	35.03%

Check the Univest Screener for live data on these steady revenue growth stocks

Institutional Holding in Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs

Institutional holding shows who is backing these steady revenue growth stocks alongside the promoter. The table uses the latest reported quarter for each. Max Healthcare has the deepest institutional backing, with FII and DII together holding 71.74% as of June 2026. Domestic institutions increased their holding over the past year in Max Healthcare (from 17.42% to 29.96%), Fortis Healthcare (from 29.79% to 32.23%) and Dr Lal PathLabs (from 17.91% to 21.59%).

Stock	Promoter	FII	DII	Public	Quarter
Max Healthcare	23.71%	41.78%	29.96%	4.56%	June 2026
Mazagon Dock	81.22%	1.72%	5.01%	12.04%	June 2026
Fortis Healthcare	31.17%	25.20%	32.23%	11.40%	June 2026
Dr Lal PathLabs	53.19%	17.36%	21.59%	7.86%	June 2026

Risks to Weigh in Steady Revenue Growth Stocks

Being careful with steady revenue growth stocks means looking at what can slow the story as well as what can speed it up. Four points matter most:

• Past growth may not repeat.
• Share prices can move sharply in either direction.
• Valuation: A low PE can also reflect slower growth, so compare each PE with the growth rate instead of reading it alone.
• Concentration: Holding all 4 names puts the allocation in one sector, so size each position to match your risk appetite.

How to Choose Between Steady Revenue Growth Stocks

Picking from steady revenue growth stocks comes down to four checks, applied in order.

1. Check balance sheet strength first, and prefer a debt-to-equity ratio below 1 for non-financial companies.
2. Compare each PE with the industry PE (48.92 to 60.75) and ask whether the growth rate justifies any gap.
3. Track net profit growth, the operating margin and the return on equity in every quarterly result.
4. Stagger entries across quarters and review institutional holding every reporting season.

Download the Univest iOS App or Univest Android App to track Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs live prices.

Conclusion

Among steady revenue growth stocks, Max Healthcare stands out for the largest market cap at Rs 85,241 crore, Mazagon Dock for the highest return on equity at 26.48%, Fortis Healthcare for 16.93% revenue growth in FY26 and Dr Lal PathLabs for the strongest latest-quarter profit growth at 27.24%. Which one suits a portfolio depends on how much valuation risk it can carry, so staggering entries and reviewing each quarterly result is a sound habit. Investors comparing steady revenue growth stocks should rank them on growth, financial strength and the price paid, and anyone who wants personalised guidance can consult a SEBI-registered advisor before acting.

Frequently Asked Questions on Steady Revenue Growth Stocks to Watch

Which are the best steady revenue growth stocks to watch for multibagger potential?

Ans. Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs are the 4 names this list highlights, with market caps of Rs 85,241 crore, Rs 82,736 crore, Rs 55,926 crore and Rs 31,620 crore respectively. Max Healthcare is notable for the largest market cap at Rs 85,241 crore. Mazagon Dock stands out for the highest return on equity at 26.48%. Fortis Healthcare offers 16.93% revenue growth in FY26. Dr Lal PathLabs brings the strongest latest-quarter profit growth at 27.24%. These are watchlist names for steady revenue growth stocks, not recommendations, so match each one to your own risk profile and time horizon.

Is Mazagon Dock a good stock for long-term investors?

Ans. Mazagon Dock has a return on equity of 26.48%, a PE of 28.99 against an industry PE of 48.92 and a market cap of Rs 82,736 crore. Net profit has compounded at 44.01% a year since FY22, and FY26 revenue rose 12.77% while June 2026 quarter net profit grew 22.12%. Long-term returns in steady revenue growth stocks depend on earnings growth and the price paid at entry, so staggering purchases and consulting a SEBI-registered advisor is sensible.

Can Max Healthcare become a multibagger from here?

Ans. Max Healthcare has already gained 149.91% in five years, so another multi-fold move would need sustained earnings growth. A multibagger outcome in steady revenue growth stocks requires earnings to keep growing faster than the market for several years. Net profit has compounded at 24.26% a year since FY22, and FY26 revenue rose 18.82%. At a PE of 58.50 against an industry PE of 60.75, valuation should be checked against that growth before investing.

What is the market cap of Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs?

Ans. As of 26 October 2026, Max Healthcare has a market cap of Rs 85,241 crore, Mazagon Dock has a market cap of Rs 82,736 crore, Fortis Healthcare has a market cap of Rs 55,926 crore and Dr Lal PathLabs has a market cap of Rs 31,620 crore. All of them qualify as midcaps. Market cap changes daily with the share price, so check the latest figure on the Univest Screener or on NSE before taking a decision on steady revenue growth stocks.

What are the risks of investing in steady revenue growth stocks?

Ans. The main risks are market swings, slower growth than expected and valuations that already reflect good news. Companies with strong balance sheets and steady earnings handle these better. Comparing each PE with growth gives a fuller picture than the PE alone.

Is Mazagon Dock trading below its industry PE?

Ans. Mazagon Dock trades at a PE of 28.99 against an industry PE of 48.92. A lower PE means investors pay less for each rupee of earnings, but it should be read with growth (net profit has compounded at 44.01% a year since FY22 and FY26 revenue rose 12.77%) and balance sheet strength before drawing a conclusion.

How much do institutions hold in Max Healthcare, Mazagon Dock, Fortis Healthcare and Dr Lal PathLabs?

Ans. As of the latest reported quarter, FII and DII together hold 71.74% of Max Healthcare (41.78% and 29.96%), 6.73% of Mazagon Dock (1.72% and 5.01%), 57.43% of Fortis Healthcare (25.20% and 32.23%) and 38.95% of Dr Lal PathLabs (17.36% and 21.59%). Rising institutional holding is a useful signal in steady revenue growth stocks, though it should be read with earnings trends rather than on its own.